A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension
- PMID: 28500078
- PMCID: PMC5501258
- DOI: 10.4049/jimmunol.1601692
A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension
Abstract
Studies in various animal models suggest an important role for pulmonary macrophages in the pathogenesis of pulmonary hypertension (PH). Yet, the molecular mechanisms characterizing the functional macrophage phenotype relative to time and pulmonary localization and compartmentalization remain largely unknown. In this study, we used a hypoxic murine model of PH in combination with FACS to quantify and isolate lung macrophages from two compartments over time and characterize their programing via RNA sequencing approaches. In response to hypoxia, we found an early increase in macrophage number that was restricted to the interstitial/perivascular compartment, without recruitment of macrophages to the alveolar compartment or changes in the number of resident alveolar macrophages. Principal component analysis demonstrated significant differences in overall gene expression between alveolar and interstitial macrophages (IMs) at baseline and after 4 and 14 d hypoxic exposure. Alveolar macrophages at both day 4 and 14 and IMs at day 4 shared a conserved hypoxia program characterized by mitochondrial dysfunction, proinflammatory gene activation, and mTORC1 signaling, whereas IMs at day 14 demonstrated a unique anti-inflammatory/proreparative programming state. We conclude that the pathogenesis of vascular remodeling in hypoxic PH involves an early compartment-independent activation of lung macrophages toward a conserved hypoxia program, with the development of compartment-specific programs later in the course of the disease. Thus, harnessing time- and compartment-specific differences in lung macrophage polarization needs to be considered in the therapeutic targeting of macrophages in hypoxic PH and potentially other inflammatory lung diseases.
Copyright © 2017 by The American Association of Immunologists, Inc.
Conflict of interest statement
The authors have no financial conflicts of interest
Figures








References
-
- Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2012;186:897–908. - PubMed
-
- Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, Van Rooijen N, Stenmark KR. Hypoxia-Induced Pulmonary Vascular Remodeling Requires Recruitment of Circulating Mesenchymal Precursors of a Monocyte/Macrophage Lineage. The American Journal of Pathology. 2006;168:659–669. - PMC - PubMed
-
- Amsellem V, Lipskaia L, Abid S, Poupel L, Houssaini A, Quarck R, Marcos E, Mouraret N, Parpaleix A, Bobe R, Gary-Bobo G, Saker M, Dubois-Randé JL, Gladwin MT, Norris KA, Delcroix M, Combadière C, Adnot S. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation. 2014;130:880–891. - PMC - PubMed
-
- Sartina E, Suguihara C, Ramchandran S, Nwajei P, Rodriguez M, Torres E, Hehre D, Devia C, Walters MJ, Penfold MET, Young KC. Antagonism of CXCR7 attenuates chronic hypoxia–induced pulmonary hypertension. Pediatr Res. 2012;71:682–688. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical